Results From Phase 3 XGEVA ® (Denosumab) Study In Patients With Multiple Myeloma Published In The Lancet Oncology
In this study, XGEVA successfully met the primary endpoint, demonstrating non-inferiority to zoledronic acid in delaying the time to first on-study skeleta...
A study shows thalidomide-based treatment carries risk, but could be an option for certain multiple myeloma patients.
FDA approves once-weekly carfilzomib/dexamethasone combo for relapsed or refractory multiple myeloma.
Conditions: Myeloma; Mucositis; Cryotherapy Effect Intervention: Other: cryotherapy Sponsor: Sahlgrenska University Hospital, Sweden Active, not recruiting
The audit of the Myeloma Institute should be able to determine if there’s any money unaccounted for in the cancer program. The accounting is expected to be final after January.
Relapse after complete response in newly diagnosed multiple myeloma: implications of duration of response and patterns of relapse, Published online: 15 October 2018; doi:10.1038/s41375-018-0271-1Relapse after complete response in newly diagnosed multiple myeloma: implications of duration of response and patterns of relapse
Authors: Barrett A, Glavey S, Sargent J, Thornton P, Murphy P, Quinn J PMID: 30310795 [PubMed]
Conclusion: In CLL, serum syndecan-1 (sCD138) levels at presentation correlate with disease burden, and higher baseline levels may predict early treatment. PMID: 30310786 [PubMed]
Authors: Yoon SS PMID: 30310779 [PubMed]
Publication date: Available online 13 October 2018Source: Clinical Lymphoma Myeloma and LeukemiaAuthor(s): AnnaLynn M. Williams, Andrea Baran, Carla Casulo, Patrick Reagan, Jonathan W. Friedberg, Margaret Helber, Jeremiah Moore, Elizabeth Baloga, Clive S. Zent, Paul M. BarrAbstractBackgroundAs oral targeted agents, such as ibrutinib, become more widely used understanding the impact of suboptimal dosing on overall and progression-free survival outside of clinical trials is imperative.MethodsData on ibrutinib discontinuation, dose reductions and treatment interruptions were collected on 170 non-Hodgkin lymphoma (NHL) and chr...
ConclusionBexarotene monotherapy is well-tolerated and has encouraging activity in PTCL that warrants further investigation. This agent should be considered for further prospective trials in this setting.